Biologic agents in cardiology

The review summarizes the results of clinical trials of biologic agents for the treatment of cardiovascular diseases. Emphasis is given to the PCSK9 inhibitors as the most wellstudied biological agents.

Key words

Biologic agents, familial hypercholesterol emia, atherosclerosis, chronic heart failure, alirocumab, evo locumab, abciximab, etanercept, infliximab, idarucizumab.